Pancreatic Cancer Treatment Market Analysis By Affected Region (Exocrine, Endocrine), By Type (Chemotherapy, Targeted Therapy, Others), By Region (North America, Europe, Asia Pacific, Latin America And MEA), And Segment Forecasts, 2014 - 2025
The global pancreatic cancer treatment market is expected to reach USD 4.2 billion in 2025, according to a new report by Grand View Research, Inc. Increasing tobacco consumption, smoking, obesity, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Thus, growing geriatric population is also expected to drive the growth during the forecast period.
According to an article published in the National Center for Biotechnology Information in 2015, pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S. Furthermore, pancreatic cancer is expected to be the second common cause of death in the U.S., by 2030. These factors together would propel the market growth in the forecast period.
Further key findings from the study suggest:
The study suggests that exocrine cancer is by far the most common type of pancreatic cancer accounting for more than 95% of the overall pancreatic cancer types
Among the treatment types, targeted therapy occupied the largest share since it is considered as the most effective treatment option, which blocks the growth and spread of cancer cells without damaging healthy cells
North America dominated the segment with the largest revenue share in 2015 due to high adoption rate of advanced treatment options and highly developed healthcare infrastructure
Asia Pacific is anticipated to show a significant growth during the forecast period, mainly due to increasing government initiatives, growing awareness regarding the treatment options for pancreatic cancer, and the availability of highly sophisticated medical infrastructure for effective treatment
Some of the major companies operating in this market are, but are not limited to, Eli Lilly and Company; Celgene Corporation; F. Hoffmann-La Roche AG; Amgen, Inc.; Novartis AG; PharmaCyte Biotech, Inc.; Clovis Oncology; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; and Pfizer, Inc.
According to an article published in the National Center for Biotechnology Information in 2015, pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S. Furthermore, pancreatic cancer is expected to be the second common cause of death in the U.S., by 2030. These factors together would propel the market growth in the forecast period.
Further key findings from the study suggest:
The study suggests that exocrine cancer is by far the most common type of pancreatic cancer accounting for more than 95% of the overall pancreatic cancer types
Among the treatment types, targeted therapy occupied the largest share since it is considered as the most effective treatment option, which blocks the growth and spread of cancer cells without damaging healthy cells
North America dominated the segment with the largest revenue share in 2015 due to high adoption rate of advanced treatment options and highly developed healthcare infrastructure
Asia Pacific is anticipated to show a significant growth during the forecast period, mainly due to increasing government initiatives, growing awareness regarding the treatment options for pancreatic cancer, and the availability of highly sophisticated medical infrastructure for effective treatment
Some of the major companies operating in this market are, but are not limited to, Eli Lilly and Company; Celgene Corporation; F. Hoffmann-La Roche AG; Amgen, Inc.; Novartis AG; PharmaCyte Biotech, Inc.; Clovis Oncology; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; and Pfizer, Inc.
CHAPTER 1 RESEARCH METHODOLOGY
1.1 Information Procurement
1.2 Data Analysis
1.3 Approaches for Market Estimation
1.3.1 Approach 1: Demand analysis & bottom-up approach
1.3.2 Approach 2: Top-down market estimation
1.3.3 Approach 3: Commodity flow and bottom-up market estimation
1.3.4 Approach 4: KoL perspective-based market sizing
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 PANCREATIC CANCER TREATMENT MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation
3.2 Market Size and Growth Prospects
3.2.1 Market driver analysis
3.2.2 Market restraint analysis
3.3 Key Opportunities Prioritized
3.4 Industry Analysis Porter’s
3.5 PESTEL Analysis
CHAPTER 4 PANCREATIC CANCER TREATMENT MARKET: AFFECTED REGION ESTIMATES & TREND ANALYSIS
4.1 Pancreatic Cancer Treatment Market: Affected Region Movement Analysis
4.2 Exocrine
4.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
4.3 Endocrine
4.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
CHAPTER 5 PANCREATIC CANCER TREATMENT MARKET: TREATMENT ESTIMATES & TREND ANALYSIS
5.1 Pancreatic Cancer Treatment Market: Treatment Movement Analysis
5.2 Chemotherapy
5.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
5.3 Targeted Therapy
5.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
5.4 Others
5.4.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
CHAPTER 6 PANCREATIC CANCER TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY AFFECTED REGION & APPLICATION
6.1 Pancreatic Cancer Treatment Market Share by Region, 2015 & 2025
6.2 North America
6.2.1 U.S.
6.2.1.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.2.1.2 Market estimates and forecasts, by application, 2014 - 2025
6.2.2 Canada
6.2.2.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.2.2.2 Market estimates and forecasts, by application, 2014 - 2025
6.3 Europe
6.3.1 U.K.
6.3.1.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.3.1.2 Market estimates and forecasts, by application, 2014 - 2025
6.3.2 Germany
6.3.2.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.3.2.2 Market estimates and forecasts, by application, 2014 - 2025
6.4 Asia Pacific
6.4.1 China
6.4.1.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.4.1.2 Market estimates and forecasts, by application, 2014 - 2025
6.4.2 Japan
6.4.2.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.4.2.2 Market estimates and forecasts, by application, 2014 - 2025
6.5 Latin America
6.5.1 Brazil
6.5.1.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.5.1.2 Market estimates and forecasts, by application, 2014 - 2025
6.5.2 Mexico
6.5.2.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.5.2.2 Market estimates and forecasts, by application, 2014 - 2025
6.6 MEA
6.6.1 South Africa
6.6.1.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.6.1.2 Market estimates and forecasts, by application, 2014 - 2025
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Strategy framework
7.2 Company Profiles
7.2.1 Eli Lily and Company
7.2.1.1 Company overview
7.2.1.2 Financial performance
7.2.1.3 Product benchmarking
7.2.1.4 Strategic initiatives
7.2.2 Celgene Corporation
7.2.2.1 Company overview
7.2.2.2 Financial performance
7.2.2.3 Product benchmarking
7.2.2.4 Strategic initiatives
7.2.3 Hoffmann-La Roche AG
7.2.3.1 Company overview
7.2.3.2 Financial performance
7.2.3.3 Product benchmarking
7.2.3.4 Strategic initiatives
7.2.4 Amgen, Inc.
7.2.4.1 Company overview
7.2.4.2 Financial performance
7.2.4.3 Product benchmarking
7.2.4.4 Strategic initiatives
7.2.5 Novartis AG
7.2.5.1 Company overview
7.2.5.2 Financial performance
7.2.5.3 Product benchmarking
7.2.5.4 Strategic initiatives
7.2.6 PharmaCyte Biotech, Inc.
7.2.6.1 Company overview
7.2.6.2 Financial performance
7.2.6.3 Product benchmarking
7.2.6.4 Strategic initiatives
7.2.7 Clovis Oncology
7.2.7.1 Company overview
7.2.7.2 Financial performance
7.2.7.3 Product benchmarking
7.2.7.4 Strategic initiatives
7.2.8 Teva Pharmaceutical Industries Ltd.
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Product benchmarking
7.2.8.4 Strategic initiatives
7.2.9 Merck & Co., Inc.
7.2.9.1 Company overview
7.2.9.2 Financial performance
7.2.9.3 Product benchmarking
7.2.9.4 Strategic initiatives
7.2.10 Pfizer, Inc.
7.2.10.1 Company overview
7.2.10.2 Financial performance
7.2.10.3 Product benchmarking
7.2.10.4 Strategic initiatives
1.1 Information Procurement
1.2 Data Analysis
1.3 Approaches for Market Estimation
1.3.1 Approach 1: Demand analysis & bottom-up approach
1.3.2 Approach 2: Top-down market estimation
1.3.3 Approach 3: Commodity flow and bottom-up market estimation
1.3.4 Approach 4: KoL perspective-based market sizing
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 PANCREATIC CANCER TREATMENT MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation
3.2 Market Size and Growth Prospects
3.2.1 Market driver analysis
3.2.2 Market restraint analysis
3.3 Key Opportunities Prioritized
3.4 Industry Analysis Porter’s
3.5 PESTEL Analysis
CHAPTER 4 PANCREATIC CANCER TREATMENT MARKET: AFFECTED REGION ESTIMATES & TREND ANALYSIS
4.1 Pancreatic Cancer Treatment Market: Affected Region Movement Analysis
4.2 Exocrine
4.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
4.3 Endocrine
4.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
CHAPTER 5 PANCREATIC CANCER TREATMENT MARKET: TREATMENT ESTIMATES & TREND ANALYSIS
5.1 Pancreatic Cancer Treatment Market: Treatment Movement Analysis
5.2 Chemotherapy
5.2.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
5.3 Targeted Therapy
5.3.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
5.4 Others
5.4.1 Market estimates and forecasts, 2014 - 2025 (USD Million)
CHAPTER 6 PANCREATIC CANCER TREATMENT MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY AFFECTED REGION & APPLICATION
6.1 Pancreatic Cancer Treatment Market Share by Region, 2015 & 2025
6.2 North America
6.2.1 U.S.
6.2.1.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.2.1.2 Market estimates and forecasts, by application, 2014 - 2025
6.2.2 Canada
6.2.2.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.2.2.2 Market estimates and forecasts, by application, 2014 - 2025
6.3 Europe
6.3.1 U.K.
6.3.1.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.3.1.2 Market estimates and forecasts, by application, 2014 - 2025
6.3.2 Germany
6.3.2.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.3.2.2 Market estimates and forecasts, by application, 2014 - 2025
6.4 Asia Pacific
6.4.1 China
6.4.1.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.4.1.2 Market estimates and forecasts, by application, 2014 - 2025
6.4.2 Japan
6.4.2.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.4.2.2 Market estimates and forecasts, by application, 2014 - 2025
6.5 Latin America
6.5.1 Brazil
6.5.1.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.5.1.2 Market estimates and forecasts, by application, 2014 - 2025
6.5.2 Mexico
6.5.2.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.5.2.2 Market estimates and forecasts, by application, 2014 - 2025
6.6 MEA
6.6.1 South Africa
6.6.1.1 Market estimates and forecasts, by affected region, 2014 - 2025
6.6.1.2 Market estimates and forecasts, by application, 2014 - 2025
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Strategy framework
7.2 Company Profiles
7.2.1 Eli Lily and Company
7.2.1.1 Company overview
7.2.1.2 Financial performance
7.2.1.3 Product benchmarking
7.2.1.4 Strategic initiatives
7.2.2 Celgene Corporation
7.2.2.1 Company overview
7.2.2.2 Financial performance
7.2.2.3 Product benchmarking
7.2.2.4 Strategic initiatives
7.2.3 Hoffmann-La Roche AG
7.2.3.1 Company overview
7.2.3.2 Financial performance
7.2.3.3 Product benchmarking
7.2.3.4 Strategic initiatives
7.2.4 Amgen, Inc.
7.2.4.1 Company overview
7.2.4.2 Financial performance
7.2.4.3 Product benchmarking
7.2.4.4 Strategic initiatives
7.2.5 Novartis AG
7.2.5.1 Company overview
7.2.5.2 Financial performance
7.2.5.3 Product benchmarking
7.2.5.4 Strategic initiatives
7.2.6 PharmaCyte Biotech, Inc.
7.2.6.1 Company overview
7.2.6.2 Financial performance
7.2.6.3 Product benchmarking
7.2.6.4 Strategic initiatives
7.2.7 Clovis Oncology
7.2.7.1 Company overview
7.2.7.2 Financial performance
7.2.7.3 Product benchmarking
7.2.7.4 Strategic initiatives
7.2.8 Teva Pharmaceutical Industries Ltd.
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Product benchmarking
7.2.8.4 Strategic initiatives
7.2.9 Merck & Co., Inc.
7.2.9.1 Company overview
7.2.9.2 Financial performance
7.2.9.3 Product benchmarking
7.2.9.4 Strategic initiatives
7.2.10 Pfizer, Inc.
7.2.10.1 Company overview
7.2.10.2 Financial performance
7.2.10.3 Product benchmarking
7.2.10.4 Strategic initiatives
LIST OF TABLES
TABLE 1 Pancreatic cancer treatment market - Industry snapshot
TABLE 2 Pancreatic cancer treatment market, by affected region, 2014 - 2025 (USD Million)
TABLE 3 Pancreatic cancer treatment market, by treatment, 2014 - 2025 (USD Million)
TABLE 4 Pancreatic cancer treatment market, by region, 2014 - 2025 (USD Million)
TABLE 5 Pancreatic cancer treatment market - Key market driver analysis
TABLE 6 Pancreatic cancer treatment market - Key market restraint analysis
TABLE 7 North America market, by affected region, 2014 - 2025 (USD Million)
TABLE 8 North America market, by treatment, 2014 - 2025 (USD Million)
TABLE 9 U.S. market, by affected region, 2014 - 2025 (USD Million)
TABLE 10 U.S. market, by treatment, 2014 - 2025 (USD Million)
TABLE 11 Canada market, by affected region, 2014 - 2025 (USD Million)
TABLE 12 Canada market, by treatment, 2014 - 2025 (USD Million)
TABLE 13 Europe market, by affected region, 2014 - 2025 (USD Million)
TABLE 14 Europe market, by treatment, 2014 - 2025 (USD Million)
TABLE 15 UK market, by affected region, 2014 - 2025 (USD Million)
TABLE 16 UK market, by treatment, 2014 - 2025 (USD Million)
TABLE 17 Germany market, by affected region, 2014 - 2025 (USD Million)
TABLE 18 Germany market, by treatment, 2014 - 2025 (USD Million)
TABLE 19 Asia Pacific market, by affected region, 2014 - 2025 (USD Million)
TABLE 20 Asia Pacific market, by treatment, 2014 - 2025 (USD Million)
TABLE 21 Japan market, by affected region, 2014 - 2025 (USD Million)
TABLE 22 Japan market, by treatment, 2014 - 2025 (USD Million)
TABLE 23 China market, by affected region, 2014 - 2025 (USD Million)
TABLE 24 China market, by treatment, 2014 - 2025 (USD Million)
TABLE 25 Latin America market, by affected region, 2014 - 2025 (USD Million)
TABLE 26 Latin America market, by treatment, 2014 - 2025 (USD Million)
TABLE 27 Brazil market, by affected region, 2014 - 2025 (USD Million)
TABLE 28 Brazil market, by treatment, 2014 - 2025 (USD Million)
TABLE 29 Mexico market, by affected region, 2014 - 2025 (USD Million)
TABLE 30 Mexico market, by treatment, 2014 - 2025 (USD Million)
TABLE 31 MEA market, by affected region, 2014 - 2025 (USD Million)
TABLE 32 MEA market, by treatment, 2014 - 2025 (USD Million)
TABLE 33 South Africa market, by affected region, 2014 - 2025 (USD Million)
TABLE 34 South Africa market, by treatment, 2014 - 2025 (USD Million)
TABLE 1 Pancreatic cancer treatment market - Industry snapshot
TABLE 2 Pancreatic cancer treatment market, by affected region, 2014 - 2025 (USD Million)
TABLE 3 Pancreatic cancer treatment market, by treatment, 2014 - 2025 (USD Million)
TABLE 4 Pancreatic cancer treatment market, by region, 2014 - 2025 (USD Million)
TABLE 5 Pancreatic cancer treatment market - Key market driver analysis
TABLE 6 Pancreatic cancer treatment market - Key market restraint analysis
TABLE 7 North America market, by affected region, 2014 - 2025 (USD Million)
TABLE 8 North America market, by treatment, 2014 - 2025 (USD Million)
TABLE 9 U.S. market, by affected region, 2014 - 2025 (USD Million)
TABLE 10 U.S. market, by treatment, 2014 - 2025 (USD Million)
TABLE 11 Canada market, by affected region, 2014 - 2025 (USD Million)
TABLE 12 Canada market, by treatment, 2014 - 2025 (USD Million)
TABLE 13 Europe market, by affected region, 2014 - 2025 (USD Million)
TABLE 14 Europe market, by treatment, 2014 - 2025 (USD Million)
TABLE 15 UK market, by affected region, 2014 - 2025 (USD Million)
TABLE 16 UK market, by treatment, 2014 - 2025 (USD Million)
TABLE 17 Germany market, by affected region, 2014 - 2025 (USD Million)
TABLE 18 Germany market, by treatment, 2014 - 2025 (USD Million)
TABLE 19 Asia Pacific market, by affected region, 2014 - 2025 (USD Million)
TABLE 20 Asia Pacific market, by treatment, 2014 - 2025 (USD Million)
TABLE 21 Japan market, by affected region, 2014 - 2025 (USD Million)
TABLE 22 Japan market, by treatment, 2014 - 2025 (USD Million)
TABLE 23 China market, by affected region, 2014 - 2025 (USD Million)
TABLE 24 China market, by treatment, 2014 - 2025 (USD Million)
TABLE 25 Latin America market, by affected region, 2014 - 2025 (USD Million)
TABLE 26 Latin America market, by treatment, 2014 - 2025 (USD Million)
TABLE 27 Brazil market, by affected region, 2014 - 2025 (USD Million)
TABLE 28 Brazil market, by treatment, 2014 - 2025 (USD Million)
TABLE 29 Mexico market, by affected region, 2014 - 2025 (USD Million)
TABLE 30 Mexico market, by treatment, 2014 - 2025 (USD Million)
TABLE 31 MEA market, by affected region, 2014 - 2025 (USD Million)
TABLE 32 MEA market, by treatment, 2014 - 2025 (USD Million)
TABLE 33 South Africa market, by affected region, 2014 - 2025 (USD Million)
TABLE 34 South Africa market, by treatment, 2014 - 2025 (USD Million)
LIST OF FIGURES
FIG. 1 Global pancreatic cancer treatment: Market segmentation
FIG. 2 Global pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 3 Pancreatic cancer treatment: Market dynamics
FIG. 4 Pancreatic cancer treatment market: Porter’s analysis
FIG. 5 Key opportunities prioritized
FIG. 6 Pancreatic cancer treatment market: PESTEL analysis
FIG. 7 Pancreatic cancer treatment market share, by affected region, 2015 & 2025
FIG. 8 Exocrine market, 2014 - 2025 (USD Million)
FIG. 9 Endocrine market, 2014 - 2025 (USD Million)
FIG. 10 Pancreatic cancer treatment market share, by type, 2015 & 2024
FIG. 11 Chemotherapy market, 2014 - 2025 (USD Million)
FIG. 12 Targeted therapy market, 2014 - 2025 (USD Million)
FIG. 13 Others market, 2014 - 2025 (USD Million)
FIG. 14 Pancreatic cancer treatment market share, by region, 2015 & 2025
FIG. 15 North America pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 16 U.S. pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 17 Canada pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 18 Europe pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 19 UK pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 20 Germany pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 21 Asia Pacific pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 22 Japan pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 23 China pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 24 Latin America pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 25 Brazil pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 26 Mexico pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 27 MEA pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 28 South Africa pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 1 Global pancreatic cancer treatment: Market segmentation
FIG. 2 Global pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 3 Pancreatic cancer treatment: Market dynamics
FIG. 4 Pancreatic cancer treatment market: Porter’s analysis
FIG. 5 Key opportunities prioritized
FIG. 6 Pancreatic cancer treatment market: PESTEL analysis
FIG. 7 Pancreatic cancer treatment market share, by affected region, 2015 & 2025
FIG. 8 Exocrine market, 2014 - 2025 (USD Million)
FIG. 9 Endocrine market, 2014 - 2025 (USD Million)
FIG. 10 Pancreatic cancer treatment market share, by type, 2015 & 2024
FIG. 11 Chemotherapy market, 2014 - 2025 (USD Million)
FIG. 12 Targeted therapy market, 2014 - 2025 (USD Million)
FIG. 13 Others market, 2014 - 2025 (USD Million)
FIG. 14 Pancreatic cancer treatment market share, by region, 2015 & 2025
FIG. 15 North America pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 16 U.S. pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 17 Canada pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 18 Europe pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 19 UK pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 20 Germany pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 21 Asia Pacific pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 22 Japan pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 23 China pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 24 Latin America pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 25 Brazil pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 26 Mexico pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 27 MEA pancreatic cancer treatment market, 2014 - 2025 (USD Million)
FIG. 28 South Africa pancreatic cancer treatment market, 2014 - 2025 (USD Million)
